checkAd
    Startseite > Aktien > Ocugen > Nachrichten
    Ocugen Aktie
    1,7680
     
    EUR
    -2,75 %
    -0,0500 EUR
    Letzter Kurs 08:52:49 Tradegate
    1,7680
     
    EUR
    4.000 STK
    Geldkurs 08:52:49
    1,7990
     
    EUR
    1.668 STK
    Briefkurs 08:52:49
    ISIN: US67577C1053 · WKN: A2PSZH · SYM: 2H51 · USA

    Neueste Nachrichten

    Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
    15.05.24 · globenewswire · Ocugen
    Ocugen Provides Business Update with First Quarter 2024 Financial Results
    14.05.24 · globenewswire · Ocugen
    Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
    10.05.24 · globenewswire · Ocugen
    Ocugen to Present at May 2024 Investor Conferences
    10.05.24 · globenewswire · Ocugen
    Ocugen to Host Conference Call on Tuesday, May 14 at 8: 30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
    03.05.24 · globenewswire · Ocugen
    Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
    02.05.24 · globenewswire · Ocugen
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
    30.04.24 · Business Wire (engl.) · Ocugen
    Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
    29.04.24 · globenewswire · Ocugen
    UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    26.04.24 · globenewswire · Ocugen
    Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    26.04.24 · globenewswire · Ocugen
    Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
    19.04.24 · globenewswire · Ocugen
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
    12.04.24 · Business Wire (engl.) · Ocugen